Skip to main content
Howard Sofen, MD, Dermatology, Los Angeles, CA

HowardLSofenMD

Dermatology Los Angeles, CA

Medical Director of Dermatology Research Associates; Associate Clinical Professor of Medicine/Dermatology Geffen School of Medicine, UCLA

Dr. Sofen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sofen's full profile

Already have an account?

  • Office

    8930 S Sepulveda Blvd
    Ste 114
    Los Angeles, CA 90045
    Phone+1 310-337-7171
    Fax+1 310-337-1081

Summary

  • Dr. Howard Sofen is a dermatologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from Drexel University College of Medicine and has been in practice 36 years. He is experienced in general dermatology, melanoma and cutaneous malignancies, and psoriasis; eczema.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1982 - 1985
  • University of Southern California/Los Angeles General Medical Center (USC/LA General)
    University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1981 - 1982
  • Drexel University College of Medicine
    Drexel University College of MedicineClass of 1981

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1982 - 2025
  • American Board of Dermatology Dermatology

Awards, Honors, & Recognition

  • Fellow (FAAD) American Academy of Dermatology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Top 5 Small Cosmetic Dermatology Sites
    Top 5 Small Cosmetic Dermatology SitesMay 4th, 2023
  • Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking Session
    Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking SessionApril 22nd, 2021
  • Improvements in Chronic Hand Eczema Seen with Oral Gusacitinib in Phase 2 Study
    Improvements in Chronic Hand Eczema Seen with Oral Gusacitinib in Phase 2 StudyNovember 19th, 2020
  • Join now to see all

Professional Memberships